Generic placeholder image

Current HIV Research

Author(s): Bahar Ahmadi-Mousavi, Somayyeh Karami-Mohajeri*, Fatemeh Dabaghzadeh, Motahareh Soltani, Zohreh Oghabian and Hamid Sharifi*

DOI: 10.2174/011570162X301403241104043813

DownloadDownload PDF Flyer Cite As
The Effects of Resveratrol in a Randomized Clinical Trial on Drug-Induced Hyperlipidemia and Psychiatric Factors in People Living with HIV

Page: [417 - 424] Pages: 8

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Introduction: People living with HIV (PLHIV) suffer from a range of consequences related to infection, including hyperlipidemia and neurologic and sleep disorders. Supplements containing phenolic compounds with high antioxidant properties can reduce these side effects. Resveratrol is a phenolic compound that improves the symptoms of diabetes, cancer, and viral infections. This study aimed to evaluate the effects of resveratrol on hyperlipidemia and neurological problems in PLHIV in Iran.

Methods: In this double-blind, randomized clinical trial, 41 PLHIV were randomly assigned to two groups: a placebo group (n=21) and a resveratrol group (n=20). Triglyceride and cholesterol levels were determined for all the subjects before and one month after they used the medication. Additionally, standard questionnaires were used to evaluate the quality of sleep, stress, depression, and quality of life of the participants. The data were analyzed via analysis of covariance in Stata 17.0.

Results: The study population did not significantly differ in terms of age (p=0.49), sex (p=0.09), marital status (p=0.90), level of education (p=0.90), duration of HIV infection (p=0.54), or mode of HIV transmission (p=0.51). The administration of resveratrol did not affect psychological parameters or blood cholesterol (p=0.091) or triglyceride (p=0.932) levels.

Conclusion: The administration of resveratrol did not affect cholesterol or triglyceride levels or the rates of depression, anxiety, sleep quality, or quality of life in PLHIV. The resveratrol supplementation in a large-scale clinical study involving more patients for a longer course of treatment may have had more significant effects on the serum levels of lipids and psychological factors.

Keywords: Acquired immunodeficiency syndrome, AIDS, resveratrol, antiretroviral drugs, HIV, lipoprotein.

Graphical Abstract

[1]
Li X, Lin C, Gao Z, et al. HIV/AIDS knowledge and the implications for health promotion programs among Chinese college students: geographic, gender and age differences. Health Promot Int 2004; 19(3): 345-56.
[http://dx.doi.org/10.1093/heapro/dah308] [PMID: 15306619]
[2]
Júnior AJB. Human immunodeficiency virus-HIV: a review. Brazilian J Surg Clin Res 2014; 9(2): 43-8.
[3]
Singh SK. Human immunodeficiency virus (HIV) infection. In: Diagnostics to Pathogenomics of Sexually Transmitted Infections. John & Wiley 2018.
[4]
Ji X, Chen Y, Faro J, Gewurz H, Bremer J, Spear GT. Interaction of human immunodeficiency virus (HIV) glycans with lectins of the human immune system. Curr Protein Pept Sci 2006; 7(4): 317-24.
[http://dx.doi.org/10.2174/138920306778017990] [PMID: 16918446]
[5]
Granich R, Gupta S, Suthar AB, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 2011; 9(6): 446-69.
[http://dx.doi.org/10.2174/157016211798038597] [PMID: 21999779]
[6]
Chemparthy DT, Kannan M, Gordon L, Buch S, Sil S. Alzheimer’s-like pathology at the crossroads of HIV-associated neurological disorders. Vaccines 2021; 9(8): 930.
[http://dx.doi.org/10.3390/vaccines9080930] [PMID: 34452054]
[7]
Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12(7): F51-8.
[http://dx.doi.org/10.1097/00002030-199807000-00003] [PMID: 9619798]
[8]
Ahmed M, Ahmed M, Mital D, Ahmed MH. Management of hypercholesterolemia in individuals living with HIV/AIDS. In: Cholesterol. Elsevier 2022; pp. 999-1020.
[9]
Bouzoni E, Perakakis N, Connelly MA, et al. PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses. Metabolism 2022; 134: 155265.
[http://dx.doi.org/10.1016/j.metabol.2022.155265] [PMID: 35820631]
[10]
Calza L. HIV infection and myocardial infarction. Curr HIV Res 2016; 14(6): 456-65.
[http://dx.doi.org/10.2174/1570162X14666160803114651] [PMID: 27492726]
[11]
Fragkou PC, Moschopoulos CD, Dimopoulou D, et al. Cardiovascular disease and risk assessment in people living with HIV: Current practices and novel perspectives. Hellenic J Cardiol 2023; 71: 42-54.
[http://dx.doi.org/10.1016/j.hjc.2022.12.013] [PMID: 36646212]
[12]
Wang LX, Heredia A, Song H, et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: Characterization, synthesis, and anti-HIV activity. J Pharm Sci 2004; 93(10): 2448-57.
[http://dx.doi.org/10.1002/jps.20156] [PMID: 15349955]
[13]
Heredia A, Davis C, Redfield R. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acquir Immune Defic Syndr 2000; 25(3): 246-55.
[http://dx.doi.org/10.1097/00126334-200011010-00006] [PMID: 11115955]
[14]
Graham NM. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 2000; 25 (Suppl. 1): S4-S11.
[http://dx.doi.org/10.1097/00126334-200010001-00002] [PMID: 11126425]
[15]
Paparizos VA, Kyriakis KP, Botsis C, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS 2000; 14(7): 903-5.
[http://dx.doi.org/10.1097/00002030-200005050-00023] [PMID: 10839604]
[16]
Gkrania-Klotsas E, Klotsas AE. HIV and HIV treatment: effects on fats, glucose and lipids. Br Med Bull 2007; 84(1): 49-68.
[http://dx.doi.org/10.1093/bmb/ldm030] [PMID: 17981955]
[17]
Mondal D, Pradhan L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004; 4(3): 287-302.
[http://dx.doi.org/10.1385/CT:4:3:287] [PMID: 15470276]
[18]
Henning RJ, Greene JN. The epidemiology, mechanisms, diagnosis and treatment of cardiovascular disease in adult patients with HIV. Am J Cardiovasc Dis 2023; 13(2): 101-21.
[PMID: 37213313]
[19]
Madzime M, Rossouw TM, Theron AJ, Anderson R, Steel HC. Interactions of HIV and antiretroviral therapy with neutrophils and platelets. Front Immunol 2021; 12: 634386.
[http://dx.doi.org/10.3389/fimmu.2021.634386] [PMID: 33777022]
[20]
Agas A, Kalluru J, Leiser B, Garcia R, Kataru H, Haorah J. Possible mechanisms of HIV neuro-infection in alcohol use: Interplay of oxidative stress, inflammation, and energy interruption. Alcohol 2021; 94: 25-41.
[http://dx.doi.org/10.1016/j.alcohol.2021.04.003] [PMID: 33864851]
[21]
Porter KM, Sutliff RL. HIV-1, reactive oxygen species, and vascular complications. Free Radic Biol Med 2012; 53(1): 143-59.
[http://dx.doi.org/10.1016/j.freeradbiomed.2012.03.019] [PMID: 22564529]
[22]
Loaiza-Cano V, Monsalve-Escudero LM, Filho CSMB, Martinez-Gutierrez M, Sousa DP. Filho CdSMB, Martinez-Gutierrez M, Sousa DPd. Antiviral role of phenolic compounds against dengue virus: A review. Biomolecules 2020; 11(1): 11.
[http://dx.doi.org/10.3390/biom11010011] [PMID: 33374457]
[23]
Singh G, Pai RS. Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS. J Control Release 2014; 194: 178-88.
[http://dx.doi.org/10.1016/j.jconrel.2014.09.002] [PMID: 25217813]
[24]
Andrae-Marobela K, Ghislain FW, Okatch H, Majinda RRT. Polyphenols: a diverse class of multi-target anti-HIV-1 agents. Curr Drug Metab 2013; 14(4): 392-413.
[http://dx.doi.org/10.2174/13892002113149990095] [PMID: 23330927]
[25]
Allard JP, Aghdassi E, Chau J, Salit I, Walmsley S. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. Am J Clin Nutr 1998; 67(1): 143-7.
[http://dx.doi.org/10.1093/ajcn/67.1.143] [PMID: 9440389]
[26]
Benedetti F, Sorrenti V, Buriani A, Fortinguerra S, Scapagnini G, Zella D. Resveratrol, rapamycin and metformin as modulators of antiviral pathways. Viruses 2020; 12(12): 1458.
[http://dx.doi.org/10.3390/v12121458] [PMID: 33348714]
[27]
Saad NM, Sekar M, Gan SH, Lum PT, Vaijanathappa J, Ravi S. Resveratrol: Latest scientific evidences of its chemical, biological activities and therapeutic potentials. Pharmacogn J 2020; 12(6): 1779-91.
[28]
Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radic Biol Med 1995; 19(4): 523-8.
[http://dx.doi.org/10.1016/0891-5849(95)00047-2] [PMID: 7590404]
[29]
Jaruga P, Jaruga B, Gackowski D, et al. Supplementation with antioxidant vitamins prevents oxidative modification of DNA in lymphocytes of HIV-infected patients. Free Radic Biol Med 2002; 32(5): 414-20.
[http://dx.doi.org/10.1016/S0891-5849(01)00821-8] [PMID: 11864781]
[30]
Liang T, Wu Z, Li Y, et al. A synthetic resveratrol analog termed Q205 reactivates latent HIV-1 through activation of P-TEFb. Biochem Pharmacol 2022; 197: 114901.
[http://dx.doi.org/10.1016/j.bcp.2021.114901] [PMID: 34971588]
[31]
Frémont L. Biological effects of resveratrol. Life Sci 2000; 66(8): 663-73.
[http://dx.doi.org/10.1016/S0024-3205(99)00410-5] [PMID: 10680575]
[32]
Izzo C, Annunziata M, Melara G, et al. The role of resveratrol in liver disease: A comprehensive review from in vitro to clinical trials. Nutrients 2021; 13(3): 933.
[http://dx.doi.org/10.3390/nu13030933] [PMID: 33805795]
[33]
Ma Y, Zheng X, Zhu P, et al. Novel resveratrol-chalcone derivatives: synthesis and biological evaluation. Mini Rev Med Chem 2019; 19(5): 424-36.
[http://dx.doi.org/10.2174/1389557518666180727165358] [PMID: 30058485]
[34]
Qasem RJ. The estrogenic activity of resveratrol: a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit Rev Toxicol 2020; 50(5): 439-62.
[http://dx.doi.org/10.1080/10408444.2020.1762538] [PMID: 32744480]
[35]
Chudzińska M, Rogowicz D, Wołowiec Ł, Banach J, Sielski S, Bujak R. Resveratrol and cardiovascular system—The unfulfilled hopes. Irish J Med Sci 2021; 190: 981-6.
[36]
Haunschild R, Marx W. On health effects of resveratrol in wine. Int J Environ Res Public Health 2022; 19(5): 3110.
[http://dx.doi.org/10.3390/ijerph19053110] [PMID: 35270803]
[37]
Khosravi A, Deyhim MR, Yari F, Nikougoftar Zarif M. Resveratrol; a double-edged sword antioxidant agent for preserving platelet cell functions during storage; Molecular Insights. Rep Biochem Mol Biol 2023; 11(4): 553-64.
[http://dx.doi.org/10.52547/rbmb.11.4.553] [PMID: 37131901]
[38]
Olas B. The antioxidant, anti-platelet and anti-coagulant properties of phenolic compounds, associated with modulation of hemostasis and cardiovascular disease, and their possible effect on COVID-19. Nutrients 2022; 14(7): 1390.
[http://dx.doi.org/10.3390/nu14071390] [PMID: 35406002]
[39]
Olas B, Wachowicz B, Saluk-Juszczak J. Zieliński T, Kaca W, Buczyński A. Antioxidant activity of resveratrol in endotoxin-stimulated blood platelets. Cell Biol Toxicol 2001; 17(2): 117-25.
[http://dx.doi.org/10.1023/A:1010962222305] [PMID: 11499695]
[40]
Wurz DA, Marcon Filho JL, Brighenti AF, Allebrandt R. Bem BPd, Rufato L. Phenolic composition of wine from’Cabernet Sauvignon’grapes subjected to leaf removal at different timing in Southern Brazil. Pesqui Agropecu Bras 2020; 55.
[41]
Xue Y, Chen H, Zhang S, et al. Resveratrol confers vascular protection by suppressing TLR4/Syk/NLRP3 signaling in oxidized low-density lipoprotein‐activated platelets. Oxid Med Cell Longev 2021; 2021(1): 8819231.
[http://dx.doi.org/10.1155/2021/8819231] [PMID: 33728029]
[42]
Tung WC, Rizzo B, Dabbagh Y, et al. Polyphenols bind to low density lipoprotein at biologically relevant concentrations that are protective for heart disease. Arch Biochem Biophys 2020; 694: 108589.
[http://dx.doi.org/10.1016/j.abb.2020.108589] [PMID: 33010229]
[43]
Wu CW, Nakamoto Y, Hisatome T, Yoshida S, Miyazaki H. Resveratrol and its dimers ε‐viniferin and δ‐viniferin in red wine protect vascular endothelial cells by a similar mechanism with different potency and efficacy. Kaohsiung J Med Sci 2020; 36(7): 535-42.
[http://dx.doi.org/10.1002/kjm2.12199] [PMID: 32118360]
[44]
Xia N, Forstermann U, Li H. Resveratrol as a gene regulator in the vasculature. Curr Pharm Biotechnol 2014; 15(4): 401-8.
[http://dx.doi.org/10.2174/1389201015666140711114450] [PMID: 25022271]
[45]
Caldeira-Dias M, Viana-Mattioli S, de Souza Rangel Machado J, Carlström M, de Carvalho Cavalli R, Sandrim VC. Resveratrol and grape juice: Effects on redox status and nitric oxide production of endothelial cells in in vitro preeclampsia model. Pregnancy Hypertens 2021; 23: 205-10.
[http://dx.doi.org/10.1016/j.preghy.2021.01.001] [PMID: 33515977]
[46]
Hsieh T-c, Wu JM. Unraveling and trailblazing cardioprotection by resveratrol. In: Resveratrol: State-of-the-Art Science and Health Applications: Actionable Targets and Mechanisms of Resveratrol. World Scientific 2019; pp. 1-28.
[47]
Bahun M, Jukić M, Oblak D, et al. Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols. Food Chem 2022; 373(Pt B): 131594.
[http://dx.doi.org/10.1016/j.foodchem.2021.131594] [PMID: 34838409]
[48]
Shirani F, Khorvash F, Arab A. Review on selected potential nutritional intervention for treatment and prevention of viral infections: possibility of recommending these for Coronavirus 2019. Int J Food Prop 2020; 23(1): 1722-36.
[http://dx.doi.org/10.1080/10942912.2020.1825483]
[49]
S FA , Madhu M, Udaya Kumar V, et al. Nutritional aspects of people living with HIV (PLHIV) amidst COVID-19 pandemic: an insight. Curr Pharmacol Rep 2022; 8(5): 350-64.
[http://dx.doi.org/10.1007/s40495-022-00301-z] [PMID: 35966952]
[50]
Silva LLG, Santos EMD, Nascimento LCPD, et al. Lipodystrophic syndrome of HIV and associated factors: a study in a university hospital. Cien Saude Colet 2020; 25(3): 989-98.
[http://dx.doi.org/10.1590/1413-81232020253.11772018] [PMID: 32159668]
[51]
van Wijk JPH, Cabezas MC. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV‐infected patients: effects of antiretroviral therapy and adipose tissue distribution. Int J Vasc Med 2012; 2012(1): 1-13.
[http://dx.doi.org/10.1155/2012/201027] [PMID: 21876813]
[52]
Jani N, Yadegarfar G, Hajishafiyee M, Azadbakht L. Antioxidants and improvement of immune system function in HIV infected patients: A review article. Majallah-i Danishkadah-i Pizishki-i Isfahan 2011; 29(135)
[53]
Mauricio KSS. HIV/AIDS: The mechanisms and consequences of oxidative stress and the benefits of antioxidants. HIV/AIDS: the mechanisms and consequences of oxidative stress and the benefits of antioxidants. PhD thesis, University of Coimbra 2019.
[54]
Gerber MT, Mondy KE, Yarasheski KE, et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004; 39(3): 419-25.
[http://dx.doi.org/10.1086/422144] [PMID: 15307011]
[55]
Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The Hospital Anxiety and Depression Scale (HADS): translation and validation study of the Iranian version. Health Qual Life Outcomes 2003; 1(1): 14.
[http://dx.doi.org/10.1186/1477-7525-1-14] [PMID: 12816545]
[56]
Farrahi Moghaddam J, Nakhaee N, Sheibani V, Garrusi B, Amirkafi A. reliability and validity of the persian version of the pittsburgh sleep quality index (PSQI-P). Sleep Breath 2012; 16(1): 79-82.
[http://dx.doi.org/10.1007/s11325-010-0478-5] [PMID: 21614577]
[57]
Burckhardt CS, Anderson KL. The Quality of Life Scale (QOLS): reliability, validity, and utilization. Health Qual Life Outcomes 2003; 1(1): 60.
[http://dx.doi.org/10.1186/1477-7525-1-60] [PMID: 14613562]
[58]
Xie HC, Han HP, Chen Z, He JP. A study on the effect of resveratrol on lipid metabolism in hyperlipidemic mice. Afr J Tradit Complement Altern Med 2013; 11(1): 209-12.
[http://dx.doi.org/10.4314/ajtcam.v11i1.33] [PMID: 24653579]
[59]
Akbari M, Tamtaji OR, Lankarani KB, et al. The effects of resveratrol on lipid profiles and liver enzymes in patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Lipids Health Dis 2020; 19(1): 25.
[http://dx.doi.org/10.1186/s12944-020-1198-x] [PMID: 32066446]
[60]
Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res 2020; 90(3-4): 279-89.
[PMID: 30789808]
[61]
Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 2013; 71(12): 822-35.
[http://dx.doi.org/10.1111/nure.12081] [PMID: 24111838]
[62]
Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus—systematic review and meta‐analysis. Mol Nutr Food Res 2015; 59(1): 147-59.
[http://dx.doi.org/10.1002/mnfr.201400173] [PMID: 25138371]
[63]
Sahebkar A, Serban C, Ursoniu S, et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2015; 189: 47-55.
[http://dx.doi.org/10.1016/j.ijcard.2015.04.008] [PMID: 25885871]
[64]
Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 2016; 51(4): 456-64.
[http://dx.doi.org/10.3109/00365521.2015.1107620] [PMID: 26784973]
[65]
Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore–Sullivan TM, Lee P. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12(12): 2092-103.
[http://dx.doi.org/10.1016/j.cgh.2014.02.024]
[66]
Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res 2014; 34(10): 837-43.
[http://dx.doi.org/10.1016/j.nutres.2014.09.005] [PMID: 25311610]
[67]
Asghari S, Asghari-Jafarabadi M, Somi MH, Ghavami SM, Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Am Coll Nutr 2018; 37(3): 223-33.
[http://dx.doi.org/10.1080/07315724.2017.1392264] [PMID: 29313746]
[68]
Wei RM, Zhang YM, Feng YZ, et al. Resveratrol ameliorates maternal separation-induced anxiety- and depression-like behaviors and reduces Sirt1-NF-kB signaling-mediated neuroinflammation. Front Behav Neurosci 2023; 17: 1172091.
[http://dx.doi.org/10.3389/fnbeh.2023.1172091] [PMID: 37273278]
[69]
Surya K, Manickam N, Jayachandran KS, Kandasamy M, Anusuyadevi M. Resveratrol mediated regulation of hippocampal neuroregenerative plasticity via SIRT1 pathway in synergy with Wnt signaling: Neurotherapeutic implications to mitigate memory loss in Alzheimer’s disease. J Alzheimers Dis 2022; 2022: 1-17.
[70]
Walker AJ, Johnson KP, Miaskowski C, Lee KA, Gedaly-Duff V. Sleep quality and sleep hygiene behaviors of adolescents during chemotherapy. J Clin Sleep Med 2010; 6(5): 439-44.
[http://dx.doi.org/10.5664/jcsm.27932] [PMID: 20957843]
[71]
Pardo CA, McArthur JC, Griffin JW. HIV neuropathy: Insights in the pathology of HIV peripheral nerve disease. J Peripher Nerv Syst 2001; 6(1): 21-7.
[http://dx.doi.org/10.1046/j.1529-8027.2001.006001021.x] [PMID: 11293804]
[72]
Cruess DG, Antoni MH, Gonzalez J, et al. Sleep disturbance mediates the association between psychological distress and immune status among HIV-positive men and women on combination antiretroviral therapy. J Psychosom Res 2003; 54(3): 185-9.
[http://dx.doi.org/10.1016/S0022-3999(02)00501-9] [PMID: 12614827]
[73]
Seay JS, McIntosh R, Fekete EM, et al. Self-reported sleep disturbance is associated with lower CD4 count and 24-h urinary dopamine levels in ethnic minority women living with HIV. Psychoneuroendocrinology 2013; 38(11): 2647-53.
[http://dx.doi.org/10.1016/j.psyneuen.2013.06.022] [PMID: 23850225]
[74]
Wightman EL, Haskell-Ramsay CF, Reay JL, et al. The effects of chronic trans -resveratrol supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in healthy, young humans. Br J Nutr 2015; 114(9): 1427-37.
[http://dx.doi.org/10.1017/S0007114515003037] [PMID: 26344014]
[75]
Benton T, Lynch K, Dubé B, et al. Selective serotonin reuptake inhibitor suppression of HIV infectivity and replication. Psychosom Med 2010; 72(9): 925-32.
[http://dx.doi.org/10.1097/PSY.0b013e3181f883ce] [PMID: 20947783]
[76]
Nolan R, Gaskill PJ. The role of catecholamines in HIV neuropathogenesis. Brain Res 2019; 1702: 54-73.
[http://dx.doi.org/10.1016/j.brainres.2018.04.030] [PMID: 29705605]